Research Article

Response of Immunotherapy to Tumour-TICLs Interactions: A Travelling Wave Analysis

Joseph Malinzi, Precious Sibanda, and Hermene Mambili-Mamoundou

School of Mathematics, Statistics, and Computer Science, University of KwaZulu-Natal, Private Bag X01, Scottsville, Pietermaritzburg 3209, South Africa

Correspondence should be addressed to Joseph Malinzi; josephmalinzi@aims.ac.za

Received 19 March 2014; Revised 10 June 2014; Accepted 19 June 2014; Published 15 July 2014

Academic Editor: Igor Leite Freire

Copyright © 2014 Joseph Malinzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There are several cancers for which effective treatment has not yet been identified. Mathematical modelling can nevertheless point out to clinicians tumour invasion properties that should be targeted to mitigate these cancers. We present a travelling wave analysis of a tumour-immune interaction model with immunotherapy. We use the geometric treatment of an apt-phase space to establish the intersection between stable and unstable manifolds. We calculate the minimum wave speed and numerical simulations are performed to support the analytical results.

1. Introduction

In travelling wave analysis, the medium moves in the direction of propagation of the wave. Travelling wave analysis is important in tumour-immune interaction dynamics since if travelling waves exist, then we may estimate the potential with which the tumour cells invade healthy tissue [1]. Tumour-immune interaction studies have revealed a lot of information regarding cancer and cancer treatments [2–9] including cancer dormancy, when tumour cells remain in a quiescent state for a long period of time without metastasizing. Cancer dormancy has been attributed to tumour-immune interactions, particularly tumour infiltrating cytotoxic lymphocytes (TICLs) [2]. Travelling wave analysis could lead to an understanding of the analytical connection between model parameters and tumour invasion properties.

Most of the standard cell invasion models are related to the Fisher-Kolmogorov equation. The Fisher-Kolmogorov equation [10, 11] is the simplest macroscopic reaction-diffusion evolution equation for modelling cancer invasion just as seen in [12]. Many authors, for example, [12–14], have used the Fisher-Kolmogorov equation in modelling diffusive tumours and the evolution of cancer on a macroscopic scale. Several studies have shown that this equation exhibits travelling wave solutions and the minimum wave speed for these

models has been estimated (see [15, 16]). The tumour-immune interaction model presented in this paper employs the Fisher-Kolmogorov equation to model the random movement of cells. The aim of this paper is to investigate the existence of travelling wave solutions in a tumour-immune interaction model with and without immunotherapy and to estimate the minimum wave speed with which tumour cells invade healthy tissue. In this way we obtain an estimate of the strength with which a tumour invades immune cells or the ability of tumour cells to resist invasion by immune cells and also identify the tumour invasion properties in the form of parameters that should be targeted to mitigate cancer in body tissue. The work presented in this paper complements the analysis done by Mambili-Mamoundou et al. [17]. They presented similar model equations, analyzed their equilibria, and found numerical solutions. The main objective in Mambili-Mamoundou et al.'s work [17] was to ascertain the cause of cancer dormancy and investigate the effect that immunotherapy has on the response of TICLs to solid tumour invasion.

2. The Model

The model considered here was derived by Mambili-Mamoundou et al. [17]. It subdivides the cell population

FIGURE 1: Schematic diagram of the local kinetic cell interactions [17].

into local concentrations of primed TICs E , tumour cells T , interleukin 2 concentration IL_2 , tumour-immune cell complex C , a chemokine α , and resting cells R . The class IL_2 represents a population of cultured immune cells that have antitumour reactivity with the tumour host. We assume that IL_2 does not necessarily bind with TICs to form a cell complex but rather stimulates the TICs to fight cancer through lymphocyte activation, growth, and differentiation. We also assume that IL_2 increases the rate of conversion of resting TICs to primed TICs (see [17, 18]). R is a class representing the population of TICs which have not yet matured or been activated by antigens. During a tumour attack on immune cells or any other body tissue infection, naive or resting TICs are primed by antigen presenting cells (APCs) in secondary lymphoid organs such as lymph nodes and spleen [19]. Figure 1 shows the cells' local kinetics.

Following the receptor-ligand kinetics theory in [20], when a tumour cell and an immune cell come into contact, it may lead to the formation of a tumour-immune complex at a binding rate k_1 which later can either lead to tumour cell death with probability p at a rate k_2p or lead to inactivation of TICs at a rate $k_2(1 - p)$. In case of the latter, the tumour-immune complex is dissociated at a rate k_{-1} . k_2 is a parameter describing the detachment rate of TICs from tumour cells, resulting in an irreversible programming of the tumour cells for lysis. Complex formation reduces both TICs and tumour cell densities and increases the complex density by k_1ET . Similarly the TICs and tumour cell densities, respectively, increase by $(k_{-1} + k_2p)C$ and $(k_{-1} + k_2(1 - p))C$, in case the tumour or immune cell dies. The binding of the primed TICs to tumour cells leads to the production of a chemokine α . The chemokine gradient defines the migration of the TICs towards the tumor by a process known as chemotaxis which is represented by $\chi \nabla \cdot (E \nabla \alpha)$ in the model, with χ being the chemotaxis constant. We assume that the rate of supply of immune cells into the region of tumour localization is ρR , where ρ is the supply rate. We consider the immune cells proliferation term to be $fC/(g_1 + T)$ and similarly the chemokine production term to be $fC/(g_3 + T)$, where f , g_1 , and g_3 are constant parameters derived from experimental results. $fC/(g_1 + T)$ is a function that explains how tumour cells proliferate as a result of interaction with immune cells. We consider that all cell densities diffuse at constant rates. We thus consider the following system of parabolic nonlinear

partial differential equations (Mambili-Mamoundou et al. [17]):

$$\begin{aligned}
 \frac{\partial E}{\partial t} &= D_1 \nabla^2 E - \chi \nabla \cdot (E \nabla \alpha) + \rho R + \frac{fC}{g_1 + T} \\
 &\quad - d_1 E - k_1 ET + (k_{-1} + k_2 p) C \\
 &\quad + \omega IL_2 \cdot R + \frac{\theta_2 E \cdot IL_2}{g_2 + IL_2} + eT, \\
 \frac{\partial T}{\partial t} &= D_2 \nabla^2 T + a_1 T (1 - b_1 T) - k_1 ET \\
 &\quad + (k_{-1} + k_2 (1 - p)) C, \\
 \frac{\partial C}{\partial t} &= k_1 ET - (k_{-1} + k_2) C, \\
 \frac{\partial \alpha}{\partial t} &= D_3 \nabla^2 \alpha + \frac{fC}{g_3 + T} - d_3 \alpha, \\
 \frac{\partial IL_2}{\partial t} &= D_4 \nabla^2 IL_2 + s_2 - d_2 IL_2, \\
 \frac{\partial R}{\partial t} &= D_5 \nabla^2 R + s_3 + a_2 R (1 - b_2 R) \\
 &\quad - \omega IL_2 \cdot R - \rho R,
 \end{aligned} \tag{1}$$

where D_i , $i = 1, 2, \dots, 5$, are diffusion coefficients of primed TICs, tumour, IL_2 , α , and resting cell densities, respectively, and ω is the rate of stimulation of resting cells into activated TICs as a result of injecting a patient with IL_2 . The capacity of IL_2 to stimulate the production of antibodies is denoted by eT and $\theta_2 E \cdot IL_2 / (g_2 + IL_2)$ is a proliferation term also considered by Kirschner and Panetta [3]. It models the stimulation of TICs by IL_2 and is of the Michaelis-Menten form (see [3]). $a_1 T (1 - b_1 T)$ and $a_2 R (1 - b_2 R)$ are logistic growth terms, respectively, modelling tumour and resting cells' growth, where a_i and b_i^{-1} , $i = 1, 2$, are, respectively, the growth rates and carrying capacities, s_2 is the IL_2 supply, and d_2 , d_3 are, respectively, the deactivation rates of IL_2 and α . s_3 , a_2 , and b_2^{-1} are, respectively, the resting cells supply rate, growth rate, and carrying capacity.

We consider a one-dimensional spatial domain on the interval $[0, x_0]$ and assume that there are two regions in this interval, one fully occupied by tumour cells and the other fully occupied by TICLs (both activated and resting). We propose that the initial interval of tumour localization is $[0, L]$, where $L = 0.2x_0$ [2]. In our model, we do not include the Heaviside function since we consider a resting cell class. We further assume that these resting cells can be recruited into the activated cell class. The boundary and initial conditions therefore are

$$\begin{aligned} \mathbf{n} \cdot \nabla E &= \mathbf{n} \cdot \nabla T = \mathbf{n} \cdot \nabla \Pi_2 = \mathbf{n} \cdot \nabla R \\ &= \mathbf{n} \cdot \nabla C = \mathbf{n} \cdot \nabla \alpha = 0 \quad \text{at } x = 0, x = x_0, \\ E(x, 0) &= \begin{cases} 0, & 0 \leq x \leq L, \\ E_0 [1 - \exp(-1000(x - L)^2)], & L \leq x \leq x_0, \end{cases} \\ R(x, 0) &= \begin{cases} 0, & 0 \leq x \leq L, \\ R_0 [1 - \exp(-1000(x - L)^2)], & L \leq x \leq x_0, \end{cases} \\ \Pi_2(x, 0) &= \Pi_{2_0}, \quad \forall x \in [0, x_0], \\ C(x, 0) &= C_0, \quad \forall x \in [0, x_0], \\ \alpha(x, 0) &= 0, \quad \forall x \in [0, x_0], \\ T(x, 0) &= \begin{cases} T_0 [1 - \exp(-1000(x - L)^2)], & 0 \leq x \leq L, \\ 0, & L \leq x \leq x_0. \end{cases} \end{aligned} \quad (2)$$

It has been shown that chemotaxis does not influence the existence of travelling wave solutions (see, e.g., [1]). We therefore do the travelling wave analysis without the effect of chemotaxis. Assuming that the formation of cellular conjugates occurs on a time scale of a few hours while that of tumour cells as well as the influx of immune cells into the spleen occurs on a much slower time scale, probably tens of hours, and nondimensionalizing the above system of (1) by taking E, T, Π_2 , and R as fractions of their initial concentrations with $t_0 = x_0/D_1$ and $x_0 = 1$ cm give

$$\begin{aligned} \frac{\partial E}{\partial t} &= \nabla^2 E + \bar{\phi}_1 R + \frac{\bar{\theta}_1 E T}{\eta_1 + T} - \psi E - \nu E T \\ &\quad + \bar{\omega}_1 \Pi_2 \cdot R + \frac{\bar{\theta}_2 E \cdot \Pi_2}{\eta_2 + \Pi_2} + \bar{e} T, \\ \frac{\partial T}{\partial t} &= \phi \nabla^2 T + \beta_1 T (1 - \beta_2 T) - \bar{\mu}_1 E T, \\ \frac{\partial \Pi_2}{\partial t} &= \xi \nabla^2 \Pi_2 + \sigma_2 - \bar{\mu}_2 \Pi_2, \\ \frac{\partial R}{\partial t} &= \zeta \nabla^2 R + \sigma_3 + \alpha_1 R (1 - \alpha_2 R) \\ &\quad - \bar{\omega}_2 \Pi_2 \cdot R - \bar{\phi}_2 R, \end{aligned} \quad (3)$$

where

$$\begin{aligned} \bar{\theta}_1 &= \theta_1 t_0, \quad \psi = d_1 t_0, \quad \bar{\theta}_2 = \theta_2 t_0, \\ \bar{e} &= \frac{e T_0 t_0}{E_0}, \quad \bar{\omega}_1 = \frac{\omega R_0 \Pi_{2_0} t_0}{E_0}, \\ \eta_1 &= \frac{g}{T_0}, \quad \eta_2 = g_2 t_0, \quad \beta_1 = a_1 t_0, \\ \beta_2 &= b_1 T_0, \quad \bar{\mu}_1 = m E_0 t_0, \\ \sigma_3 &= \frac{s_3 t_0}{R_0}, \quad \nu = l T_0 t_0, \quad \phi = D_2 t_0, \\ \xi &= D_4 t_0, \quad \bar{\eta}_3 = g_3 t_0, \\ \bar{\phi}_1 &= \frac{\rho R_0 t_0}{E_0}, \quad \sigma_2 = \frac{\sigma_2 t_0}{\Pi_{2_0}}, \\ \zeta &= D_5 t_0, \quad \bar{\mu}_2 = \mu_2 t_0, \\ \bar{\omega}_2 &= \omega \Pi_{2_0} t_0, \quad \alpha_1 = a_2 t_0, \\ \alpha_2 &= b_2 R_0, \quad \bar{\phi}_2 = \rho t_0, \\ l &= K k_2 (1 - p), \quad \bar{\theta}_1 = f K, \\ m &= K k_2 p, \quad K = \frac{k_1}{(k_{-1} + k_2)}. \end{aligned} \quad (4)$$

The boundary and initial conditions are, respectively,

$$\begin{aligned} \frac{\partial E}{\partial x}(0, x) &= \frac{\partial \Pi_2}{\partial x}(0, t) = \frac{\partial R}{\partial t}(0, x) = \frac{\partial T}{\partial x}(0, t) = 0, \\ \frac{\partial E}{\partial x}(1, t) &= \frac{\partial R}{\partial x}(1, t) = \frac{\partial \Pi_2}{\partial x}(1, t) = \frac{\partial T}{\partial x}(1, t) = 0, \\ E(x, 0) &= \begin{cases} 0, & 0 \leq x \leq L, \\ [1 - \exp(-1000(x - L)^2)], & L \leq x \leq 1, \end{cases} \\ R(x, 0) &= \begin{cases} 0, & 0 \leq x \leq L, \\ [1 - \exp(-1000(x - L)^2)], & L \leq x \leq 1, \end{cases} \\ \Pi_2(x, 0) &= \Pi_{2_0}, \quad \forall x \in [0, 1], \\ T(x, 0) &= \begin{cases} [1 - \exp(-1000(x - L)^2)], & 0 \leq x \leq L, \\ 0, & L \leq x \leq 1. \end{cases} \end{aligned} \quad (5)$$

3. Travelling Wave Solutions

In this section we investigate whether model (3) exhibits travelling wave solutions or not. We use the geometric treatment of an apt-phase space to establish the intersection between stable and unstable manifolds, a method also employed by Bellomo et al. [1] in investigating travelling wave solutions. The gist of this method is to establish the presence of a heteroclinic orbit joining two different equilibrium points in the phase space. We specify a travelling coordinate $z = x - ct$, where c the travelling wave speed is greater than zero ($c > 0$),

and let $\tilde{E}(z) = E(x, t)$, $\tilde{T}(z) = T(x, t)$, $\tilde{\text{IL}}_2(z) = \text{IL}_2(x, t)$, and $\tilde{R}(z) = R(x, t)$. For simplicity, we drop the tildes and the system (3) is transformed into

$$\begin{aligned} -c \frac{dE}{dz} &= \frac{d^2 E}{dz^2} + \bar{\phi}_1 R + \frac{\bar{\theta}_1 E T}{\eta_1 + T} - \psi E - \nu E T \\ &\quad + \bar{\omega}_1 \text{IL}_2 R + \frac{\bar{\theta}_2 E \text{IL}_2}{\eta_2 + \text{IL}_2} + \bar{e} T, \\ -c \frac{dT}{dz} &= \phi \frac{d^2 T}{dz^2} + \beta_1 T (1 - \beta_2 T) - \bar{\mu}_1 E T, \\ -c \frac{d\text{IL}_2}{dz} &= \xi \frac{d^2 \text{IL}_2}{dz^2} + \sigma_2 - \bar{\mu}_2 \text{IL}_2, \\ -c \frac{dR}{dz} &= \zeta \frac{d^2 R}{dz^2} + \sigma_3 + \alpha_1 R (1 - \alpha_2 R) \\ &\quad - \bar{\omega}_2 \text{IL}_2 R - \bar{\phi}_2 R. \end{aligned} \quad (6)$$

For simple phase space analysis, we define variables

$$\begin{aligned} E_1 &= \frac{dE}{dz}, & T_1 &= \frac{dT}{dz}, \\ \text{IL}_{21} &= \frac{d\text{IL}_2}{dz}, & R_1 &= \frac{dR}{dz}, \end{aligned} \quad (7)$$

and (6) are transformed into a system of autonomous first order differential equations as follows:

$$\frac{dX}{dz} = f(X), \quad \text{where } X = \begin{pmatrix} E_1 \\ E \\ T_1 \\ T \\ \text{IL}_{21} \\ \text{IL}_2 \\ R_1 \\ R \end{pmatrix} \in \mathbb{R}^8, \quad (8)$$

$f(X)$

$$= \begin{bmatrix} -cE_1 - \bar{\phi}_1 R - \frac{\bar{\theta}_1 E T}{\eta_1 + T} + \psi E + \nu E T - \bar{\omega}_1 \text{IL}_2 R - \frac{\bar{\theta}_2 E \text{IL}_2}{\eta_2 + \text{IL}_2} - \bar{e} T \\ E_1 \\ \frac{1}{\phi} (-cT_1 - \beta_1 (1 - \beta_2 T) + \mu_1 E T) \\ T_1 \\ \frac{1}{\xi} (-c\text{IL}_{21} - \sigma_2 + \mu_2 \text{IL}_2) \\ \text{IL}_{21} \\ \frac{1}{\zeta} (-cR_1 - \sigma_3 - \alpha_1 R (1 - \alpha_2 R) + \bar{\omega}_2 \text{IL}_2 R + \bar{\phi}_2 R) \\ R_1 \end{bmatrix}, \quad (9)$$

with boundary conditions

$$\begin{aligned} \lim_{z \rightarrow -\infty} (E_1, E, T_1, T, \text{IL}_{21}, \text{IL}_2, R_1, R) \\ = X^0 = (0, E, 0, 0, 0, \text{IL}_2, 0, R), \end{aligned}$$

TABLE 1: Dimensional parameter values for model (1).

Parameter	Estimated value	Units	Source
a	0.18	day^{-1}	[2]
k_1	1.3×10^{-7}	$\text{day cells}^{-1} \text{cm}$	[2]
k_2	7.2	day^{-1}	[2]
d_1	0.0412	day^{-1}	[2]
g	2.02×10^7	cells cm^{-1}	[2]
b	2.0×10^{-9}	$\text{cells}^{-1} \text{cm}$	[2]
k_{-1}	24	day^{-1}	[2]
p	0.9997	Dimensionless	[2]
f	0.2988×10^8	$\text{day}^{-1} \text{cells cm}^{-1}$	[2]
s	1.36×10^4	$\text{day}^{-1} \text{cells cm}^{-1}$	[2]
D_1	10^{-6}	$\text{cm}^2 \text{day}^{-1}$	[2]
D_2	10^{-6}	$\text{cm}^2 \text{day}^{-1}$	[2]
θ_2	0.1245	day^{-1}	[3]
e	$0 \leq c \leq 0.005$	day^{-1}	[3]
g_2	10^7	cm^3	[3]
d_2	10	day^{-1}	[18]
a_2	0.0245	day^{-1}	[18]
b_2	$\frac{1}{10^7}$	cell^{-1}	[18]
ρ	6.4×10^{-6}	$\text{cells}^{-1} \text{day}^{-1}$	[18]

$$\begin{aligned} \lim_{z \rightarrow +\infty} (E_1, E, T_1, T, \text{IL}_{21}, \text{IL}_2, R_1, R) \\ = X^1 = (0, E, 0, T, 0, \text{IL}_2, 0, R), \end{aligned} \quad (10)$$

where X^0 and X^1 correspond to the equilibrium points of the system (8).

The system (8) can be regarded as an eigenvalue problem because the wave velocity c is unknown. We take $c = 20$, a value that numerically gives rise to travelling wave solutions. We chose this value after simulating the system of (3). There are several other values of c that can give rise to travelling wave solutions. In the next section, we calculate a critical wave speed below which travelling wave solutions do not exist. We find a heteroclinic connection between X^0 and X^1 , where, after substituting parameter values in Table 1,

$$X^0 \approx \begin{pmatrix} 0 \\ 0.0001 \\ 0 \\ 0 \\ 0 \\ 0.7968 \\ 0 \\ 0.001 \end{pmatrix}, \quad X^1 \approx \begin{pmatrix} 0 \\ 5.8934 \\ 0 \\ 0.7986 \\ 0 \\ 0.7968 \\ 0 \\ 0.0002 \end{pmatrix}. \quad (11)$$

Here, X^0 and X^1 are equilibrium points of the system (8). Our interest is to establish the existence of an orbit $X_{\text{con}}(z)$ that satisfies

$$\lim_{z \rightarrow -\infty} X_{\text{con}}(z) = X^0, \quad \lim_{z \rightarrow +\infty} X_{\text{con}}(z) = X^1. \quad (12)$$

The existence of such an orbit would imply that travelling wave solutions do exist [1].

We consider the linearization

$$\frac{dX}{dz} = Df(X^0)X, \quad \frac{dX}{dz} = Df(X^1)X, \quad (13)$$

of the vector field f at the equilibrium points X^0 and X^1 , respectively. From the Jacobian

$$Df(x) = \begin{pmatrix} -c & A_1 & 0 & A_2 & 0 & A_3 & 0 & -I\omega_1 & -\phi_1 \\ 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & \frac{T\mu_1}{\phi} & -\frac{c}{\phi} & A_4 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & -\frac{c}{\xi} & \mu_2 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & \frac{\omega_2}{\xi} & -\frac{c}{\xi} & A_5 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 1 & 0 & 0 \end{pmatrix}, \quad (14)$$

where

$$\begin{aligned} A_1 &= T\nu - \frac{T\theta_1}{T + \eta_1} - \frac{I\theta_2}{I + \eta_2} + \psi, \\ A_2 &= E\bar{e} + E\nu - \frac{E\eta_1\theta_1}{(T + \eta_1)^2}, \\ A_3 &= \frac{E\eta_2\theta_2}{(I + \eta_2)^2}, \\ A_4 &= \frac{2T\beta_1\beta_2}{\phi} + \frac{E\mu_1}{\phi} - \frac{\beta_1}{\phi} - R\omega_1, \\ A_5 &= \frac{2R\alpha_1\alpha_2}{\xi} + \frac{I\omega_2 + \phi_2}{\xi} - \frac{\alpha_1}{\xi}, \end{aligned} \quad (15)$$

we determine the spectrum of the matrices $Df(X^0)$ and $Df(X^1)$. For parameter values in Table 1, $Df(X^0)$ has eight real eigenvalues (213.22, 27.11, 20, 15.68, -5.35×10^{-9} , -7.11 , -15.48 , -193.22), four positive and four negative. The four positive eigenvalues imply the existence of a 4-dimensional unstable manifold $W^u(X^0)$. Similarly, $Df(X^1)$ has eight eigenvalues (213.2, 27.11, 20, -15.68 , -0.0002 , -7.11 , -15.48 , -193.22), three positive and five negative, implying the existence of a 5-dimensional stable manifold $W^s(X^1)$. From this result, we note that

$$\dim(W^u(X^0)) + \dim(W^s(X^1)) = \dim \mathbb{R}^8 + 1. \quad (16)$$

Equation (16) suggests that $W^u(X^0)$ and $W^s(X^1)$ intersect transversally along a one-dimensional curve in the eight-dimensional phase space. This is because the solutions of the system (8) lie in eight dimensions (8D) but the summation of the dimension of the stable and unstable manifolds is nine

(9D) just as shown in (16) (see [1, 21]). If this is the case, then this curve would define a generic heteroclinic connection [1]. This therefore confirms that the system (1) exhibits travelling wave solutions for certain parameter values.

4. Minimum Wave Speed

In the previous section, we established that (3) exhibits travelling wave solutions. In this section, we calculate the minimum wave speed for model (3) with ($IL_2 \neq 0$) and without ($IL_2 = 0$) treatment connecting the tumour-free equilibrium point to the cancer dormant equilibrium point. In this section we seek the minimum wave speed c . We apply the same technique used by Chahrazed [22] and Maidana and Yang [23] in determining c . This technique involves analyzing the phase space by characterizing the equilibrium points of the autonomous system. The minimum wave speed corresponds to a change in the eigenvalues of the travelling-wave differential equations at the equilibrium point ahead of the wave.

To calculate the minimum wave speed, we impose a condition that X^0 , the tumour-free equilibrium point of (8), must not oscillate. In other words, the eigenvalues λ_i corresponding to this equilibrium point must have real values; that is, $\lambda_i \in \mathbb{R}$. We seek the travelling wave speed both with and without immunotherapy.

4.1. No Treatment Case. With $IL_2 = 0$, the tumour-free equilibrium point of the system (8) is

$$\begin{aligned} X^0 &= (0, E^*, 0, 0, 0, R^*), \quad \text{where} \\ E^* &= \frac{(\alpha_1 - \phi_2 + \sqrt{4\alpha_1\alpha_2\sigma_3 + (\alpha_1 - \phi_2)^2})\phi}{2\alpha_1\alpha_2\psi}, \\ R^* &= \frac{\alpha_1 - \phi_2 + \sqrt{4\alpha_1\alpha_2\sigma_3 + (\alpha_1 - \phi_2)^2}}{2\alpha_1\alpha_2}. \end{aligned} \quad (17)$$

For the equilibrium point X^0 to be biologically meaningful, E^* and R^* must be positive. E^* and R^* are positive provided that

$$\alpha_1 + \sqrt{4\alpha_1\alpha_2\sigma_3 + (\alpha_1 - \phi_2)^2} \geq \phi_2. \quad (18)$$

The eigenvalues λ_i , $i = 1, 2, \dots, 6$, corresponding to X^0 are

$$\lambda_1 = -\frac{1}{2}c + \frac{1}{2}\sqrt{c^2 + 4\psi}, \quad (19)$$

$$\lambda_2 = -\frac{1}{2}c - \frac{1}{2}\sqrt{c^2 + 4\psi}, \quad (20)$$

$$\lambda_3 = -\frac{c + \sqrt{c^2 + 4\left(\sqrt{4\alpha_1\alpha_2\sigma_3 + (\alpha_1 - \phi_2)^2}\right)\xi}}{2\xi}, \quad (21)$$

$$\lambda_4 = -\frac{c - \sqrt{c^2 + 4 \left(\sqrt{4\alpha_1\alpha_2\sigma_3 + (\alpha_1 - \phi_2)^2} \right) \xi}}{2\xi}, \quad (22)$$

$$\begin{aligned} \lambda_5 &= - \left(\alpha_1\alpha_2c\psi \right. \\ &\quad \left. + \sqrt{2\sqrt{(4\alpha_1\alpha_2\sigma_3 + (\alpha_1 - \phi_2)^2)}\alpha_1\alpha_2\mu_1\phi^2\psi - C + D} \right) \\ &\quad \times (2\alpha_1\alpha_2\phi\psi)^{-1}, \end{aligned} \quad (23)$$

$$\begin{aligned} \lambda_6 &= - \left(\alpha_1\alpha_2c\psi \right. \\ &\quad \left. - \sqrt{2\sqrt{(4\alpha_1\alpha_2\sigma_3 + (\alpha_1 - \phi_2)^2)}\alpha_1\alpha_2\mu_1\phi^2\psi - C + D} \right) \\ &\quad \times (2\alpha_1\alpha_2\phi\psi)^{-1}, \end{aligned} \quad (24)$$

where

$$\begin{aligned} C &= (4\alpha_1^2\alpha_2^2\beta_1\phi - \alpha_1^2\alpha_2^2c^2)\psi^2, \\ D &= 2(\alpha_1^2\alpha_2\mu_1\phi^2 - \alpha_1\alpha_2\mu_1\phi^2\phi_2)\psi. \end{aligned} \quad (25)$$

The first four eigenvalues (19)–(22) are real. Therefore (23) or (24) should determine the minimum wave speed which we obtain by setting

$$\sqrt{2\sqrt{(4\alpha_1\alpha_2\sigma_3 + (\alpha_1 - \phi_2)^2)}\alpha_1\alpha_2\mu_1\phi^2\psi - C + D} = 0, \quad (26)$$

since we require $\lambda_{5,6}$ to be real. Solving for c in (26) gives

$$\begin{aligned} c &= \left(4\beta_1\phi + \frac{2\mu_1\phi^2\phi_2}{\alpha_1\alpha_2\psi} - \frac{2\mu_1\phi^2}{\alpha_2\psi} \right. \\ &\quad \left. - \frac{2\sqrt{4\alpha_1\alpha_2\sigma_3 + \alpha_1^2 - 2\alpha_1\phi_2 + \phi_2^2}\mu_1\phi^2}{\alpha_1\alpha_2\psi} \right)^{1/2}. \end{aligned} \quad (27)$$

Substituting parameter values from Table 1 into (27) gives $c \geq 4.176$. This indicates that the minimum wave speed $c_{\min}$ for the tumour-immune interaction model without immunotherapy is approximately 4.176.

4.2. Treatment Case. With $\Pi_2 \neq 0$, the tumour-free equilibrium points of the system (8) are

$$X^0 = (0, \bar{E}, 0, 0, 0, \bar{\Pi}_2, 0, \bar{R}), \quad \text{where}$$

$$\begin{aligned} \bar{E} &= \frac{(\mu_2\phi_1 + \omega_1\sigma_2)(\eta_2\mu_2 + \sigma_2)(p_1 - p_2 + \sqrt{(A+P) - (B+Q)})}{2(\eta_2\mu_2\psi + \psi\sigma_2 - \sigma_2\theta_2)\alpha_1\alpha_2\mu_2^2} \\ &\geq 0, \end{aligned}$$

$$\bar{\Pi}_2 = \frac{\sigma_2}{\mu_2},$$

$$\bar{R} = \frac{p_1 - p_2 + \sqrt{(A+P) - (B+Q)}}{2\alpha_1\alpha_2\mu_2} \geq 0,$$

provided $(A+P) \geq (B+Q)$, $(\eta_2\mu_2 + \sigma_2)\psi > \sigma_2\theta_2$,

$$p_1 + \sqrt{(A+P) - (B+Q)} \geq p_2, \quad \text{where}$$

$$A = 4\alpha_1\alpha_2\mu_2^2\sigma_3 + \alpha_1^2\mu_2^2, \quad B = 2\alpha_1\mu_2^2\phi_2,$$

$$P = \mu_2^2\phi_2^2 + \omega_2^2\sigma_2^2, \quad Q = 2(\alpha_1\mu_2\omega_2 - \mu_2\omega_2\phi_2)\sigma_2,$$

$$p_1 = \alpha_1\mu_2, \quad p_2 = \mu_2\phi_2 + \omega_2\sigma_2. \quad (28)$$

The eigenvalues λ_i , $i = 1, 2, \dots, 8$, corresponding to X^0 (with immunotherapy) are

$$\lambda_1 = -\frac{c + \sqrt{4\mu_2\xi^2 + c^2}}{2\xi}, \quad (29)$$

$$\lambda_2 = -\frac{c - \sqrt{4\mu_2\xi^2 + c^2}}{2\xi}, \quad (30)$$

$$\lambda_3 = -\frac{c\mu_2 + \sqrt{c^2\mu_2^2 + 4\sqrt{(A+P) - (B+Q)}\mu_2\xi}}{2\mu_2\xi}, \quad (31)$$

$$\lambda_4 = -\frac{c\mu_2 - \sqrt{c^2\mu_2^2 + 4\sqrt{(A+P) - (B+Q)}\mu_2\xi}}{2\mu_2\xi}, \quad (32)$$

$$\begin{aligned} \lambda_5 &= - \left(c\eta_2\mu_2 + c\sigma_2 \right. \\ &\quad \left. + ((\eta_2\mu_2 + \sigma_2) \right. \\ &\quad \left. \times (c^2\eta_2\mu_2 + 4\eta_2\mu_2\psi + (c^2 + 4\psi)\sigma_2 + 4\sigma_2\theta_2))^{1/2} \right) \\ &\quad \times 2(\eta_2\mu_2 + \sigma_2)^{-1}, \end{aligned} \quad (33)$$

FIGURE 2: Travelling wave solutions of the system (3) for different travelling wave coordinates without treatment.

$$\begin{aligned} \lambda_6 &= -\left(c\eta_2\mu_2 + c\sigma_2 \right. \\ &\quad \left. - \left((\eta_2\mu_2 + \sigma_2) \right. \right. \\ &\quad \left. \left. \times \left(c^2\eta_2\mu_2 + 4\eta_2\mu_2\psi + (c^2 + 4\psi)\sigma_2 + 4\sigma_2\theta_2 \right) \right)^{1/2} \right) \\ &\quad \times 2(\eta_2\mu_2 + \sigma_2)^{-1}, \end{aligned} \quad (34)$$

$$\lambda_7 = -\frac{-\Gamma_1 + \sqrt{(A+P) - (B+Q) - C + D + \Gamma_2\alpha_1\alpha_2}}{2(\alpha_1\alpha_2\eta_2\mu_2^2\phi\psi + \alpha_1\alpha_2\mu_2\phi\psi\sigma_2 - \alpha_1\alpha_2\mu_2\phi\sigma_2\theta_2)}, \quad (35)$$

$$\lambda_8 = -\frac{-\Gamma_1 - \sqrt{(A+P) - (B+Q) - C + D + \Gamma_2\alpha_1\alpha_2}}{2(\alpha_1\alpha_2\eta_2\mu_2^2\phi\psi + \alpha_1\alpha_2\mu_2\phi\psi\sigma_2 - \alpha_1\alpha_2\mu_2\phi\sigma_2\theta_2)}, \quad (36)$$

where

$$\begin{aligned} \Gamma_1 &= -\alpha_1\alpha_2c\eta_2\mu_2^2\psi + \alpha_1\alpha_2c\mu_2\psi\sigma_2 - \alpha_1\alpha_2c\mu_2\sigma_2\theta_2, \\ \Gamma_2 &= J \left(4A + \alpha_1^2\mu_2^2 - 2\alpha_1\mu_2^2\phi_2 + \mu_2^2\phi_2^2 + \omega_2^2\sigma_2^2 \right. \\ &\quad \left. - 2(\alpha_1\mu_2\omega_2 - \mu_2\omega_2\phi_2)\sigma_2 \right)^{1/2}, \end{aligned} \quad (37)$$

where $J = 2(\eta_2\mu_1\mu_2^2\phi\phi_1 + \mu_1\omega_1\phi\sigma_2^2 + (\eta_2\mu_1\mu_2\omega_1\phi + \mu_1\mu_2\phi\phi_1)\sigma_2)$.

FIGURE 3: Travelling wave solutions of the system (3) for different travelling wave coordinates with immunotherapy.

The first six eigenvalues (29)–(34) are real provided that the conditions we have imposed for positivity of the tumour-free equilibrium point are fulfilled. Equation (35) or (36) should therefore determine the conditions for the existence of a minimum wave speed. We set $\Gamma_1 - \sqrt{(A + P) - (B + Q) - C + D + \Gamma_2 \alpha_1 \alpha_2} = 0$ and substituted parameter values in Table 1. The result gave the value $c \geq 4.176$ as in the case without treatment. This implies that the minimum wave speed for model (3) for both with and without treatment is the same. In other words, immunotherapy may possibly not influence the strength with which the tumour cells attack immune cells because the minimum wave speed with or without clinical treatment is the same. Fisher's

equation exhibits travelling wave solutions for $c \geq 2$ [24]. The minimum wave velocity which we obtained is greater than two and therefore not a violation of the minimum wave speed for Fisher's equation.

5. Numerical Simulations

Using the parameter values in Table 1, we simulate model (3). These parameter values were obtained from data where the murine B cell lymphoma was used as an experimental model of tumour dormancy in mice [25]. The kinetic parameter values that were obtained in this experiment are shown

in Table 1. We assumed that R and IL_2 diffuse at the same rate as TICLs (i.e., $D_1 = D_4 = D_5 = 10^{-6}$) and used the diffusivity value 10^{-6} for immune cells by Matzavinos et al. [2]. We took the travelling wave speed to be $c = 20$ and implemented the simulations in python using a Runge-Kutta numerical method. The numerical simulations (see Figures 2 and 3) indicate that the system of (3) exhibits travelling wave solutions for certain parameter values. This supports the analytical results on the existence of travelling waves in Section 3. Figures 2 and 3, respectively, show the numerical travelling wave solutions for model (3) without and with clinical treatment, and for different travelling wave coordinates. They depict solutions that are periodic and oscillating around a stable equilibrium state. These solutions describe heterogeneous cell distributions with a relatively low tumour cell density. The travelling wave solutions indicate that tumour cells invade immune cells at a high potential. The minimum wave speed obtained in the previous section indicated that the model exhibits travelling wave solutions for $c \geq 4$. This is consistent with our numerical simulations for which we used $c = 20$.

6. Conclusions

Many biological and physical phenomena can be described by reaction-diffusion equations. However not many nonlinear reaction-diffusion equations are integrable. It is therefore imperative to find other quantitative methods for tackling such nonlinear systems. The objective of this study was to use a quantitative method to investigate travelling wave solutions of a tumour-immune interaction model and also identify the tumour invasion properties in the form of parameters that should be targeted to mitigate cancer by estimating the minimum wave speed. We investigated the existence of travelling wave solutions and estimated the minimum wave speed of the wave solutions by analyzing the model phase space. The existence of travelling wave solutions confirmed that a tumour attacks immune cells at full potential. The expression from which the minimum wave speed was calculated determined the parameters that need to be targeted to eradicate cancer in body tissue. We simulated model (3) and compared the results to analytical results. The numerical travelling wave solutions depicted periodic cell densities with a low tumor level, oscillating about a stable equilibrium state. These solutions depict cancer dormancy which has been observed in several cancers, for example, osteogenic sarcomas, basal-cell carcinoma, and breast cancers, and they also imply that the tumour cells attack the immune cells at their full potential.

Equation (27) highlights the main parameters ($\beta_1, \alpha_1, \alpha_2, \sigma_3, \phi, \phi_1, \mu_1$) involved in tumour invasion corresponding to tumour growth rate, resting TICLs' growth rate, carrying capacity of the resting TICLs, resting cells' supply, diffusion rate of the tumour cells, and the local kinetic interaction parameters (tumour cell death and inactivation of TICLs).

The results obtained in this paper are similar to those in Matzavinos and Chaplain [26]. In their work, they performed a travelling wave analysis of a model describing the growth

of a tumour in the presence of an immune system response. Their results showed that indeed a tumor attacks immune cells at full potential since their model exhibited travelling wave solutions. In the future, we hope to consider diffusion in higher dimension due to the fact that body tissue geometry is highly intricate.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contribution

Precious Sibanda and Hermene Mambili-Mamoundou are coauthors.

Acknowledgment

The authors are grateful for financial support from the University of KwaZulu-Natal.

References

- [1] N. Bellomo, M. Chaplain, and E. De Angelis, *Selected Topics in Cancer Modelling: Genesis, Evolution, Immune Competition, and Therapy*, Birkhäuser, Boston, Mass, USA, 2000.
- [2] A. Matzavinos, M. A. Chaplain, and V. A. Kuznetsov, "Mathematical modelling of spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour," *Mathematical Medicine and Biology*, vol. 21, no. 1, pp. 1–34, 2004.
- [3] D. Kirschner and J. C. Panetta, "Modeling immunotherapy of the tumor-immune interaction," *Journal of Mathematical Biology*, vol. 37, no. 3, pp. 235–252, 1998.
- [4] A. d'Onofrio, "A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences," *Physica D: Nonlinear Phenomena*, vol. 208, no. 3–4, pp. 220–235, 2005.
- [5] N. V. Stepanova, "Course of the immune reaction during the development of a malignant tumour," *Biophysics*, vol. 24, no. 1, pp. 220–235, 1980.
- [6] H. P. de Vlarar and J. A. González, "Dynamic response of cancer under the influence of immunological activity and therapy," *Journal of Theoretical Biology*, vol. 227, no. 3, pp. 335–348, 2004.
- [7] V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor, and A. S. Perelson, "Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis," *Bulletin of Mathematical Biology*, vol. 56, no. 2, pp. 295–321, 1994.
- [8] L. G. de Pillis and A. Radunskaya, "A mathematical model of immune response to tumor invasion," *Computational Fluid and Solid Mechanics: Proceedings of the Second MIT Conference on Computational Fluid and Solid Mechanics*, vol. 56, pp. 1661–1668, 2003.
- [9] A. Donofrio, "Tumor-immune system interaction: modeling the tumor-stimulated proliferation of effectors and immunotherapy," *Mathematical Models & Methods in Applied Sciences*, vol. 16, no. 8, pp. 1375–1401, 2006.

- [10] P. Breuer, W. Huber, and F. Petruccione, "Fluctuation effects on wave propagation in a reaction-diffusion process," *Physica D: Nonlinear Phenomena*, vol. 73, no. 1, pp. 259–273, 1993.
- [11] R. A. Fisher, "The wave of advance of advantageous genes," *Annals of Eugenics*, vol. 7, no. 4, pp. 355–369, 1937.
- [12] E. Konukoglu, O. Clatz, B. H. Menze et al., "Ayache Image guided personalization of reaction-diffusion type tumour growth models using modified anisotropic Eikonal equations," *Journal of Medical Imaging*, vol. 29, no. 1, pp. 78–95, 2010.
- [13] K. Swanson, E. Alvord, and J. Murray, "Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy," *Journal of Cancer*, vol. 86, no. 1, pp. 14–18, 2002.
- [14] G. Cruywagen, D. Woodward, P. Tracqui, G. Bartoo, J. Murray, and E. Alvord, "The modelling of diffusive tumours," *Journal of Biological Systems*, vol. 3, no. 1, pp. 937–945, 1995.
- [15] W. Huang and Y. Wu, "Minimum wave speed for a diffusive competition model with time delay," *Journal of Applied Analysis and Computation*, vol. 1, no. 2, pp. 205–218, 2011.
- [16] Q. Wang and X.-Q. Zhao, "Spreading speed and traveling waves for the diffusive logistic equation with a sedentary compartment," *Dynamics of Continuous, Discrete & Impulsive Systems*, vol. 13, no. 2, pp. 231–246, 2006.
- [17] H. Mambili-Mamboundou, P. Sibanda, and J. Malinzi, "Effect of immunotherapy on the response of TICLs to solid tumour invasion," *Mathematical Biosciences*, vol. 249, pp. 52–59, 2014.
- [18] F. S. Borges, K. C. Iarosz, H. P. Ren et al., "Model for tumour growth with treatment by continuous and pulsed chemotherapy," *Biosystems*, vol. 116, pp. 43–48, 2014.
- [19] N. Zhang and M. J. Bevan, "CD8(+) T cells: foot soldiers of the immune system," *Immunity*, vol. 35, no. 2, pp. 161–168, 2011.
- [20] D. A. Lauffenburger and J. J. Linderman, *Models for Binding, Trafficking, and Signalling*, Oxford University Press, New York, NY, USA, 1993.
- [21] P. Ashwin, M. V. Bartuccelli, T. J. Bridges, and S. A. Gourley, "Travelling fronts for the KPP equation with spatio-temporal delay," *Zeitschrift für angewandte Mathematik und Physik ZAMP*, vol. 53, no. 1, pp. 103–122, 2002.
- [22] L. Chahrazed, "Global stability and spatial spread of a nonlinear epidemic model," *European Scientific Journal*, vol. 9, no. 6, pp. 167–179, 2013.
- [23] N. A. Maidana and H. M. Yang, "A spatial model to describe foot and mouth disease dissemination," *Journal of Mathematics and Applied Computation*, vol. 12, no. 1, pp. 11–20, 2013.
- [24] J. A. Sherratt, "On the transition from initial data to travelling waves in the Fisher-KPP equation," *Dynamics and Stability of Systems*, vol. 13, no. 2, pp. 167–174, 1998.
- [25] H. Siu, E. S. Vitetta, R. D. May, and J. W. Uhr, "Tumour dormancy: regression of BCL tumour and induction of a dormant tumour state in mice chimeric at the major histocompatibility complex," *Journal of Immunology*, vol. 137, no. 1, pp. 1376–1382, 1986.
- [26] A. Matzavinos and M. A. J. Chaplain, "Traveling-wave analysis of a model of the immune response to cancer," *Comptes Rendus Biologies*, vol. 327, no. 11, pp. 995–1008, 2004.